Posted by Michael Wonder on 26 Mar 2019
Institute for Clinical and Economic Review to assess upadacitinib and other treatments for rheumatoid arthritis
26 March 2019 - Open Input now being accepted; review will be subject to public deliberation at upcoming CTAF meeting.
The Institute for Clinical and Economic Review (ICER) will conduct an update to its 2017 assessment on therapies for rheumatoid arthritis, including new evidence on upadacitinib (AbbVie), which is currently under review by the FDA with an expected decision around August 2019.
The assessment will be publicly discussed during a meeting of the California Technology Assessment Forum in October of 2019, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
